Canadian General Medical Center Complex Company (4021) fair value: what the stock is really worth
We calculate from audited financials what Canadian General Medical Center Complex Company is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Canadian General Medical Center Complex Company for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range 3.75 SAR – 8.92 SAR · fair‑value band 2.14 SAR – 5.00 SAR · the 5.36 SAR price screens above the 3.26 SAR fair value. Dashed = 300-day average. As of Sep 13, 2026.
Canadian General Medical Center Complex Company engages in the management of hospitals and health centers in the Kingdom of Saudi Arabia.
Show more
Canadian General Medical Center Complex Company engages in the management of hospitals and health centers in the Kingdom of Saudi Arabia. The company offers ambulance transport, medical examinations and training, home healthcare and ambulance services, medical coverage for events, medical support at industrial sites, medical support at construction sites, and medical support at onshore and offshore sites, as well as operates medical centers. It also trades in hospital tools and equipment and ambulances. The company was incorporated in 2008 and is headquartered in Dammam, the Kingdom of Saudi Arabia.
Stock analysis
Canadian General Medical Center Complex Company (4021) currently trades at 5.36 SAR, while our model-based Fair Value estimate is 3.26 SAR, implying the stock looks roughly 64.4% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 3.95 SAR per share, and 2 of the 26 models we run sit above the 5.36 SAR price.
Bear case: the Asset-Based group reads lowest at 0.8400 SAR, and 24 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: 2.14 SAR (bear) to 5.00 SAR (bull), the price of 5.36 SAR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Canadian General Medical Center Complex Company reported revenue of 148M SAR in FY2025 versus 70.6M SAR in FY2021, a compound +20.4%/yr. Reported net income was 10.5M SAR in FY2025, compounding −7.1%/yr from FY2021.
Key figures
Market cap 440M SAR (≈ $117M) · P/E ratio 67.0 · P/S ratio 4.74 · EPS (TTM) 0.0800 SAR · Dividend yield 2.4% · Net margin 7.1% · Return on equity 6.5% · Return on assets (EBIT) 13.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 42% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 0% fair-value upside, at −39%, 4021 screens richer than that median.
Fair Value models
Bear 2.14 SARFair Value 3.26 SARBull 5.00 SAR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+33.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.2%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.5%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−5.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.8%
Dividend (yield on the price)2.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 12%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.6%
Yearly growth needed for the next five years to justify today's price.
Compare Canadian General Medical Center Complex Company with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 255 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score73 · Top 25%
Fair Value upside−46% · Bottom 25%
Profitability
Return on equity (TTM)7% · Below median
Return on assets9% · Top 25%
Net margin (TTM)4% · Below median
Operating margin (TTM)11% · Above median
Growth and dividend
Revenue growth26% · Top 25%
Dividend yield (TTM)2.4% · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (TTM)67.0× · Priciest 25%
P/B1.22× · Cheaper than median
P/S (TTM)0.75× · Cheaper than median
P/FCF11.2× · Priciest 25%
EV/EBITDA5.4× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 29
FUTURE (revenue growth)100· sector 27
PAST (return on equity)26· sector 31
HEALTH (low debt)0· sector 90
DIVIDEND (yield)49· sector 42
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Canadian General Medical Center Complex Company Fair Value". https://www.fairvalue-calculator.com/stock/4021
Frequently asked questions
Is Canadian General Medical Center Complex Company (4021) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 3.26 SAR versus a price of 5.36 SAR, about −39% upside (overvalued).
What is the fair value of 4021?
Our model-based fair value for Canadian General Medical Center Complex Company is 3.26 SAR (as of Sep 13, 2026), built from audited fundamentals. The current price: 5.36 SAR.
What is the quality score of 4021?
Canadian General Medical Center Complex Company has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Canadian General Medical Center Complex Company (4021)?
Our model-based price target is the fair value of 3.26 SAR (as of Sep 13, 2026) from 26 valuation models. Cautious scenario 2.14 SAR, optimistic scenario 5.00 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Canadian General Medical Center Complex Company stock forecast for 2026?
Our models put fair value at 3.26 SAR, about −39% upside versus a price of 5.36 SAR (overvalued). Cautious scenario 2.14 SAR, optimistic scenario 5.00 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Canadian General Medical Center Complex Company (4021)?
Canadian General Medical Center Complex Company reported trailing-twelve-month revenue of about 156M SAR (latest available figure, as of Sep 13, 2026).
Does Canadian General Medical Center Complex Company pay a dividend?
Canadian General Medical Center Complex Company currently shows a dividend yield of about 2.43% relative to its recent price (as of Sep 13, 2026).
What growth is priced into Canadian General Medical Center Complex Company (4021)?
For today's price to be fair in a discounted-cash-flow model, Canadian General Medical Center Complex Company would have to grow free cash flow by +25.6 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +18.2 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of 4021 use?
Our models discount Canadian General Medical Center Complex Company at 11.8 %: a base by market capitalisation (micro), damped by beta 0.37, country premium for Saudi Arabia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Canadian General Medical Center Complex Company that is +25.6 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Canadian General Medical Center Complex Company (4021) delivered so far?
Over the past 5 years revenue at Canadian General Medical Center Complex Company grew +18.2 % a year. The price currently implies +25.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Canadian General Medical Center Complex Company (4021) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Canadian General Medical Center Complex Company (+25.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Canadian General Medical Center Complex Company (4021)?
The free-cash-flow yield on the price is 2.62 %: that much free cash flow Canadian General Medical Center Complex Company produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Canadian General Medical Center Complex Company (4021)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Canadian General Medical Center Complex Company it is 3.26 SAR per share (as of Sep 13, 2026), against a price of 5.36 SAR. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Canadian General Medical Center Complex Company stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 4021 trades above its calculated fair value: price 5.36 SAR, fair value 3.26 SAR, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4021?
No. The price is what the market pays today (5.36 SAR); the fair value is what the company's own numbers justify (3.26 SAR). For Canadian General Medical Center Complex Company the two are 2.10 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Canadian General Medical Center Complex Company worth?
The market values Canadian General Medical Center Complex Company at about 440M SAR (market capitalisation, as of Sep 13, 2026). Per share that is 5.36 SAR; our models calculate a fair value of 3.26 SAR per share.
What do the bullish and bearish scenarios say about 4021?
Our models span a range for Canadian General Medical Center Complex Company: cautious scenario 2.14 SAR, base 3.26 SAR, optimistic 5.00 SAR per share (as of Sep 13, 2026, price 5.36 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4021?
Canadian General Medical Center Complex Company trades at a price-to-earnings ratio of 67.0 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 3.26 SAR is built from several models across several years. Other multiples: P/B 1.2, P/S 0.8, EV/EBITDA 5.4.
How solid is the balance sheet of Canadian General Medical Center Complex Company (4021)?
Balance-sheet figures for Canadian General Medical Center Complex Company (as of Sep 13, 2026): return on equity 6.5%. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is 4021 from its 52-week high?
Canadian General Medical Center Complex Company trades at 5.36 SAR, about 42% below its 52-week high of 9.16 SAR and 3% above the low of 5.18 SAR (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 3.26 SAR is for.
Which stocks are comparable to Canadian General Medical Center Complex Company?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Canadian General Medical Center Complex Company stock attractive at the current price?
The data as of Sep 13, 2026: price 5.36 SAR, calculated fair value 3.26 SAR (−39%), Quality Score 73/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4021 calculated?
We run Canadian General Medical Center Complex Company through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3.26 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Canadian General Medical Center Complex Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Canadian General Medical Center Complex Company right now?
A high-quality business (quality 73/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (5.00 SAR). The favourable scenario is already priced in. A fairly wide model range (2.14 SAR to 5.00 SAR) leaves room in how you read the outcome.
Key figures of Canadian General Medical Center Complex Company
How large is the market capitalisation of Canadian General Medical Center Complex Company (4021)?
The market capitalisation of Canadian General Medical Center Complex Company is 440M SAR (≈ $117M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Canadian General Medical Center Complex Company (4021)?
The price-to-sales ratio of Canadian General Medical Center Complex Company is 4.74 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Canadian General Medical Center Complex Company (4021)?
Earnings per share at Canadian General Medical Center Complex Company are 0.0800 SAR (price ÷ EPS = P/E 67.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Canadian General Medical Center Complex Company (4021)?
The dividend yield of Canadian General Medical Center Complex Company is 2.4% (payout 163%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Canadian General Medical Center Complex Company (4021)?
The net margin of Canadian General Medical Center Complex Company is 7.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Canadian General Medical Center Complex Company (4021)?
The return on equity (ROE) of Canadian General Medical Center Complex Company is 6.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Canadian General Medical Center Complex Company (4021)?
On an EBIT basis the return on assets of Canadian General Medical Center Complex Company is 13.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Canadian General Medical Center Complex Company (4021)?
The operating margin of Canadian General Medical Center Complex Company is 10.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Canadian General Medical Center Complex Company (4021)?
Revenue at Canadian General Medical Center Complex Company is growing +26.4% versus a year earlier (3y avg +22.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Canadian General Medical Center Complex Company (4021)?
Earnings per share at Canadian General Medical Center Complex Company are growing −59.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Canadian General Medical Center Complex Company (4021) carry?
The net debt of Canadian General Medical Center Complex Company is 1.8M SAR (fiscal year 2025, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Canadian General Medical Center Complex Company in the live analysis
One click puts Canadian General Medical Center Complex Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
